Get started
Author

Rafael Álvarez-Gallego

Observed names: R Alvarez Gallego, R. Alvarez Gallego, R. Gallego, R. Álvarez, R. Álvarez Gallego, Rafael Alvarez, Rafael Alvarez Gallego, Rafael Alvarez-Gallego, Rafael Álvarez, Rafael Álvarez Gallego
Observed institutions: Universidad San Pablo CEU, Instituto de Salud Carlos III, Hospital Clínico San Carlos, Sanofi (Spain), Fundación Instituto Valenciano de Oncología, Institut Català d'Oncologia, Hospital Universitario Miguel Servet, Hospital Clínic de Barcelona, Corporació Sanitària Parc Taulí, HM Hospitales, University Hospital HM Puerta del Sur, Instituto Ramón y Cajal de Investigación Sanitaria, Hospital Del Mar, Parc de Salut, Hospital Universitario HM Sanchinarro, Centro de Investigación Biomédica en Red de Cáncer, Hospital Universitario Ramón y Cajal, Camilo José Cela University
ORCID: 0000-0002-3167-8039
Observed ORCID: 0000-0002-3167-8039
OpenAlex ID: A5023415126
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
2021 · Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, et al. · Journal for ImmunoTherapy of Cancer · 115
PDF
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
2022 · Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, et al. · Journal for ImmunoTherapy of Cancer · 105
PDF
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma
2017 · Benedetto Ielpo, Riccardo Caruso, et al. · Surgical Oncology · 73
DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through MAFG Overexpression in Cancer Cells
2017 · Olga Vera, Julia Jimenez, et al. · Theranostics · 68
PDF
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer
2009 · Ana Belén Custodio, José Luis González-Larriba, et al. · Journal of Thoracic Oncology · 65
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab
2016 · Rodrigo A. Toledo, Antonio Cubillo, et al. · Oncotarget · 59
PDF
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
2019 · Johanna C. Bendell, Tamara Sauri, et al. · The Oncologist · 49
PDF
Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
2018 · Rodrigo A. Toledo, Elena Garralda, et al. · Clinical Cancer Research · 48
PDF
EGFR polymorphisms as predictors of clinical outcome in patients with advanced colorectal cancer (ACRC) treated with cetuximab and panitumumab
2008 · E. Carcereny, S. Castellvi-Bel, et al. · Journal of Clinical Oncology · 44
From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer
2018 · Andrés Muñoz Martín, Manuel Hidalgo, et al. · Journal of Cancer · 42
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
2016 · M. Hidalgo, R. Álvarez, et al. · Clinical & Translational Oncology · 40
PDF
Therapeutic management of epithelial ovarian cancer during pregnancy
2012 · L. Minig, L. Otaño, et al. · Clinical & Translational Oncology · 24
Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer
2021 · Javier Andrés Soto, Carlos Rodríguez-Antolín, et al. · Clinical Epigenetics · 17
PDF
511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial
2024 · C. Santos Vivas, J. Vidal Barrull, et al. · Annals of Oncology · 16
PDF
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)
2022 · Jorge Aparicio, Anna C. Virgili Manrique, et al. · Clinical & Translational Oncology · 16
PDF
Management of hyperbilirubinaemia in pancreatic cancer patients
2018 · R. Álvarez, A. Carrato, et al. · European Journal of Cancer · 14
Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial
2019 · R. Garcia-Carbonero, M. Gil Martín, et al. · Annals of Oncology · 13
LBA33 Circulating tumor (ct) DNA-guided anti-EGFR rechallenge strategy in metastatic colorectal cancer (mCRC): Final results of the phase II randomized CITRIC trial
2025 · C. Montagut, J. Vidal, et al. · Annals of Oncology · 10
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer
2014 · Antonio Cubillo, Jesús Rodriguez-Pascual, et al. · American Journal of Clinical Oncology · 9
Antitumor activity of nab-paclitaxel and gemcitabine in resectable pancreatic cancer.
2012 · Rafael Alvarez-Gallego, Antonio Cubillo, et al. · Journal of Clinical Oncology · 9
P-118 Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
2022 · C. Santos Vivas, F. Salva, et al. · Annals of Oncology · 8
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer
2018 · Antonio Cubillo, Rafael Álvarez-Gallego, et al. · American Journal of Clinical Oncology · 8
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
2025 · Rafael Álvarez-Gallego, Roberto Pazo-Cid, et al. · Therapeutic Advances in Medical Oncology · 6
Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy
2025 · Enrique Sanz-Garcia, Paloma Peinado, et al. · Journal of Gastrointestinal Oncology · 5
A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations.
2021 · Milind M. Javle, Robin Kate Kelley, et al. · Journal of Clinical Oncology · 5
Works count: 69
Citation count: 909
H-index: 15
I10-index: 18
Year
Topic
Type